Luca Benatti sold $174k of QNCX
director at Quince Therapeutics, Inc.. 50,000 shares at an average of $3.47, traded Dec 26, 2025, filed Dec 29, 2025.
Score components
- +15RoleDirector
- +11Trade size$174k at market
- +20Share of holdings soldSold 56% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -6.5%, 3m -97.0%, 6m -97.3%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000912282-25-001469, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 26, 2025 | SOpen-market sale Common Stock | -50,000 | $3.47 | $174k | 39,179 | Dec 29, 2025 |
Related signals
Other insiders at Quince Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 64Notable | Quince Therapeutics, Inc. | Dirk Thye CEO AND CHIEF MEDICAL OFFICER | $107k 154,500 shares | +22% | |
| 58Moderate | Quince Therapeutics, Inc. | Charles S. Ryan PRESIDENT | $31k 48,387 shares | +65% | |
| 46Moderate | Quince Therapeutics, Inc. | Brendan Hannah CHIEF BUSINESS OFFICER AND COO | $24k 38,924 shares | +15% | |
| 36Weak | QNCXbuy Quince Therapeutics, Inc. | David Lamond director | $69k 67,881 shares | +3% | |
| 35Weak | QNCXbuy Quince Therapeutics, Inc. | David Lamond director | $58k 57,369 shares | +3% | |
| 29Weak | QNCXbuy Quince Therapeutics, Inc. | David Lamond director | $41k 43,134 shares | +2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.